Trial Profile

Phase IIa trial of CX 1739 in patients with central sleep apnoea

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CX 1739 (Primary)
Indications Sleep apnoea syndrome
Focus Therapeutic Use

Most Recent Events

11 Jan 2016 The company will present an update about this trial at the Biotech Showcase 2016, according to a RespireRx Pharmaceuticals media release.
01 May 2015 This trial will be discussed at the NewYorkBIO 25th Anniversary Conference in May 2015, according to a Cortex Pharmaceuticals media release.
08 Apr 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com